Cytek Biosciences, Inc.

For the period ended Mar 31, 2026. Filed May 7, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

CTKB$5.79-1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

	Three months ended March 31,
(In thousands, except share and per share data)	2026	2025
Revenue, net:
Product	$28,779	$28,110
Service	15,356	13,347
Total revenue, net	44,135	41,457
Cost of sales:
Product	15,921	15,529
Service	6,960	5,771
Total cost of sales	22,881	21,300
Gross profit	21,254	20,157
Operating expenses:
Research and development	9,604	9,725
Sales and marketing	11,646	12,509
General and administrative	18,467	12,898
Total operating expenses	39,717	35,132
Loss from operations	(18,463)	(14,975)
Other income (expense):
Interest expense	(262)	(291)
Interest income	787	508
Other income, net	565	3,492
Total other income, net	1,090	3,709
Loss before income taxes	(17,373)	(11,266)
Provision for income taxes	1,493	136
Net loss	$(18,866)	$(11,402)
Net loss, basic and diluted	$(18,866)	$(11,402)
Net loss per share, basic	$(0.15)	$(0.09)
Net loss per share, diluted	$(0.15)	$(0.09)
Weighted-average shares used in calculating net loss per share, basic	128,704,934	128,339,481
Weighted-average shares used in calculating net loss per share, diluted	128,704,934	128,339,481
Comprehensive loss:
Net loss	$(18,866)	$(11,402)
Foreign currency translation adjustment, net of tax	328	(560)
Unrealized loss on marketable securities	(201)	(65)
Net comprehensive loss	$(18,739)	$(12,027)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.